Therapeutic Asset Ratings
162 results matching 1 filter
128,359 assets · 8,667 sponsors · 3,127 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Irinotecan
Advanced Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
Letrozole
HR+/HER2+ Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
Orelabrutinib
Primary Central Nervous System Hodgkin Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
PREDNISONE TABLETS
Lenalidomide
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
Recombinant Mutant Human Tumor Necrosis Factor
peritoneal carcinomatosis
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
Rimegepant
Vestibular Migraine
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
Tafolecimab
Extensive Disease Small Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
Tafolecimab
small cell lung carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
Thiotepa
glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
Toripalimab
Breast Adenocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
Toripalimab
estrogen-receptor positive breast cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
VENLOR
HR+/HER2+ Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
(+)-VINCRISTINE
Advanced Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
(+)-VINCRISTINE
Lenalidomide
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
VITAMIN D
HR+/HER2+ Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(53)
cc-5013
Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2/3
CCC
(53)
6-(3-(4-(O-METHOXYPHENYL)-1-PIPERAZINYL)PROPYLAMINO)-1,3-DIMETHYLURACIL
ischemic stroke
Second Affiliated Hospital, School of Medicine, Zhejiang University
P3
CCC
(52)
Empagliflozin
Acute Ischemic Stroke
Second Affiliated Hospital, School of Medicine, Zhejiang University
P3
CCC
(52)
Esmolol
Ischemic Stroke
Second Affiliated Hospital, School of Medicine, Zhejiang University
P3
CCC
(52)
Terazosin
Ischemic Stroke
Second Affiliated Hospital, School of Medicine, Zhejiang University
P3
CCC
(52)
Tucidinostat
Liver Metastases
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2/3
CCC
(52)
Benmelstobart
primary peritoneal carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(51)
tj0113
Parkinson disease
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(51)
Egfr/B7H3 Car-T
glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P1/2
CCC
(50)
Atirizumab
hepatocellular carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CCC
(48)
Showing 76 to 100 of 162 assets
Previous
Page 4 of 7
Next